What is the current stock price of Cellbxhealth PLC (ANPCF)?

As of the latest market data, Cellbxhealth PLC (ANPCF) is trading at $0.01. The stock has seen a loss of 0.00% today.

Does Cellbxhealth PLC (ANPCF) pay a dividend?

Based on current data, Cellbxhealth PLC does not have a confirmed active dividend policy.

What is the market cap of Cellbxhealth PLC?

The current market capitalization of Cellbxhealth PLC (ANPCF) is approximately unavailable.

ANPCF

Cellbxhealth PLC·Healthcare

0.01

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0152W H: $0.16

ANPCF NEWS

proactiveinvestors.com

Feb 13

Enbridge reports record 2025 earnings, reaffirms 2026 guidance

Enbridge Inc (TSX:ENB) on Friday reported record financial results for 2025, driven by higher earnings across its operations, and reaffirmed its 2026...

proactiveinvestors.co.uk

Feb 13

CelLBxHealth shares rise 3% as company continues to focus on cost base

Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p on Thursday after the company announced it would discontinue its United States Food and Drug Administration establishment licence and device listing for its Parsortix system. The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support cancer research and drug development, said the decision reflected its revised business model and customer usage patterns.

proactiveinvestors.co.uk

Feb 13

CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth

CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment licence and device listing for the Parsortix system as it seeks to strengthen cost discipline and match its regulatory approach with current commercial priorities. The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support research, drug development and clinical oncology, said the decision reflected its revised business model and customer usage patterns.

proactiveinvestors.com

Feb 13

CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth

CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment...

proactiveinvestors.com

Jan 16

Nasdaq, Dow Jones little changed as TSMC settles tech jitters

1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...

proactiveinvestors.co.uk

Jan 16

CelLBxHealth backed for rebound by broker

CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4.0p price target, implying more than 300% upside from current levels, after the company confirmed that forecasts for 2026 to 2028 remain intact.

Company Profile

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

119

IPO Date

2014-01-23

Beta

0.27

Websitecellbxhealth.com↗